1
|
Pre- and Post-Treatment Patient-Reported Financial Toxicity in Head and Neck Cancer: Identifying Influential Factors and Clinical Significance. Int J Radiat Oncol Biol Phys 2023; 117:e241-e242. [PMID: 37784951 DOI: 10.1016/j.ijrobp.2023.06.1170] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Head and neck cancer patients are at high-risk for financial stress due to the often complex, time-consuming, and expensive treatments that can impact physical function and quality of life. It is important to identify factors that affect financial toxicity early on in treatment and to help mitigate their effects. The goals of this study are to assess patient-reported financial toxicity prior to and after completion of radiation therapy (RT) and to uncover any interactions with socioeconomic factors, quality of life, treatment satisfaction, and treatment adherence. MATERIALS/METHODS A total of 80 patients who were evaluated for RT to the head and neck region between July 2021 and December 2022 and had completed surveys prior to the initiation of RT were included. Surveys included the FACIT-COST and FACIT-TS-G. Patient clinical information and demographics were collected. Linear regression was used to evaluate categorical variables and Pearson correlation was used to evaluate continuous variables and their associations with COST. RESULTS The median pre-RT COST was 29.5 (range 4-44) with lower scores indicating worse financial toxicity. The majority of patients were white (69%), non-Hispanic (75%), and English-speaking (75%). 65% had Medicare, 14% had Medicaid, and 21% had other insurance. 60 of 80 (75%) patients ultimately underwent RT at our institution. 34 (57%) missed at least one day of scheduled RT fractions and 11 (14%) patients had G-tubes placed. Lower COST was associated with decreased age, thyroid primary disease, advanced stage, metastatic disease, Medicaid insurance, Hispanic ethnicity, unemployment, and G-tube placement. Higher COST was associated with cutaneous primary disease and ability to speak English, while Medicare insurance trended toward significance. 18 of 80 patients (23%) completed follow-up surveys post-RT and 9 reported a decrease in COST. At baseline, the standard deviation of the COST was 10.6. Effect size was defined as the number of standard deviation change. Mean decrease in COST was 9.4 (effect size of 89%). Mean FACT-TS-G was lower, indicating decreased treatment satisfaction, for these patients as compared to those that had the same or increased COST compared to baseline, (17.4 vs. 22.7, p < 0.01). There were more missed RT days, 4 vs. 1, and G-tube placements, 2 vs. 0, in those with decreased COST as well. CONCLUSION Worse baseline financial toxicity was associated with younger age, advanced stage, metastatic disease, Medicaid insurance, unemployment, and G-tube placement. Those that reported worsened financial toxicity after RT reported worse treatment satisfaction and had more missed RT days and G-tube placements. These findings support work to better understand financial toxicity as it may predict those at higher risk of missing treatments, particularly crucial considering prolonged RT duration is linked to poorer outcomes. Future efforts will focus on automating early referrals to case managers and social work services for these patients.
Collapse
|
2
|
Severity of Financial Toxicity for Patients Receiving Palliative Radiation Therapy. Int J Radiat Oncol Biol Phys 2023; 117:e234-e235. [PMID: 37784933 DOI: 10.1016/j.ijrobp.2023.06.1153] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Patients receiving palliative radiotherapy (RT) are often at their most vulnerable state, but the impact of financial toxicity on their health and quality of life (QOL) is not well-described. We set out to determine the degree of financial toxicity in a population undergoing palliative RT. MATERIALS/METHODS A review of patients referred for palliative RT at our site was conducted. Financial toxicity was determined with COST-FACIT, and previously suggested grading cutoffs were used. Additional patient-reported outcome (PRO) instruments included the EORTC overall health and quality of life questions and the FACIT-TS-G (treatment satisfaction). Multiple imputations by chained equations using predictive mean matching were used for incomplete responses. Spearman's rank correlation coefficient, Kruskal-Wallis testing, and linear regressions were used to measure associations. RESULTS A total of 53 patients were identified who had completed PRO surveys between May 2021 and December 2022. Median COST was 25 (range 0-44), with lower scores indicating greater financial toxicity. 49% reported grade 0 financial toxicity (COST ≥26), 32% had grade 1 financial toxicity (COST 14-25), 19% had grade 2 financial toxicity (COST 1-13), and 6% had grade 3 financial toxicity (COST = 0). Overall, cancer caused financial hardship among 45%. Higher COST was moderately associated with higher overall health (rho = 0.36, p = 0.02) and weakly associated with higher QOL (rho = 0.28, p = 0.07). From a demographic standpoint, median area family income from census tract data was $98,598 (range $32,303-$190,833), and higher income was associated with higher COST (rho = 0.47, p<0.001). Having Medicare (beta = 13.8, p = 0.003) or private (beta = 13.5, p = 0.001) coverage (rather than Medicaid) were associated with less financial toxicity, whereas having an underrepresented minority background (beta = -13.2, p<0.001), or having a non-English language preference (rho = 0.40, p = 0.003) were associated with greater financial toxicity. Median time from diagnosis was 12.9 mo, and 40% of patients had ≥2 prior systemic therapies. The median RT dose was 25 Gy (range 4-45 Gy). The most common irradiated sites included spine (24%), non-spine bones (21%), brain (18%), and lung/mediastinum (18%). COST was not associated with number of prior systemic therapies (p = 0.31), RT dose (p = 0.83), RT technique (p = 0.86), or treatment satisfaction (p = 0.34). Median follow up was 8.0 months, and median 6-month survival was 83% (95% CI 73%-95%). Inferior OS was associated with more prior systemic therapies (HR 3.43, p = 0.03), but not with COST (HR 1.01, p = 0.67). CONCLUSION Financial toxicity was seen in approximately half of patients receiving palliative RT. Patient-reported overall health, Medicaid coverage, and area income correlated well with financial toxicity, but the investigated clinical characteristics did not. This supports the hypothesis that financial toxicity is common and a unique factor that should be measured in cancer patients.
Collapse
|
3
|
Comparing genomic and epigenomic features across species using the WashU Comparative Epigenome Browser. Genome Res 2023:gr.277550.122. [PMID: 37156621 DOI: 10.1101/gr.277550.122] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2022] [Accepted: 05/03/2023] [Indexed: 05/10/2023]
Abstract
Genome browsers have become an intuitive and critical tool to visualize and analyze genomic features and data. Conventional genome browsers display data/annotations on a single reference genome/assembly; there are also genomic alignment viewer/browsers that help users visualize alignment, mismatch, and rearrangement between syntenic regions. However, there is a growing need for a comparative epigenome browser that can display genomic and epigenomic datasets across different species and enable users to compare them between syntenic regions. Here, we present the WashU Comparative Epigenome Browser. It allows users to load functional genomic datasets/annotations mapped to different genomes and display them over syntenic regions simultaneously. The browser also displays genetic differences between the genomes from single nucleotide variants (SNVs) to structural variants (SVs) to visualize the association between epigenomic differences and genetic differences. Instead of anchoring all datasets to the reference genome coordinates, it creates independent coordinates of different genome assemblies to faithfully present features and data mapped to different genomes. It uses a simple, intuitive genome-align track to illustrate the syntenic relationship between different species. It extends the widely used WashU Epigenome Browser infrastructure and can be expanded to support multiple species. This new browser function will greatly facilitate comparative genomic/epigenomic research, as well as support the recent growing needs to directly compare and benchmark the T2T CHM13 assembly and other human genome assemblies.
Collapse
|
4
|
Prognostic Value of Repeated Peak Oxygen Uptake Measurements in LVAD Patients - Follow Up on PRO-VAD Study. J Heart Lung Transplant 2023. [DOI: 10.1016/j.healun.2023.02.1644] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023] Open
|
5
|
Cell-Free DNA Enhances Pathologist Interrater Reliability at the Assessment of Acute Rejection on Endomyocardial Biopsy, on Behalf of the GRAfT Investigators. J Heart Lung Transplant 2023. [DOI: 10.1016/j.healun.2023.02.1524] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023] Open
|
6
|
Validation of the Heartmate 3 Risk Score in a Real World Patient Cohort. J Heart Lung Transplant 2023. [DOI: 10.1016/j.healun.2023.02.1590] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023] Open
|
7
|
Dysregulated Circulating Proteins in Cellular and Antibody-Mediated Rejection, on Behalf of the Graft Investigators. J Heart Lung Transplant 2023. [DOI: 10.1016/j.healun.2023.02.146] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023] Open
|
8
|
Improvement in Peak Oxygen Uptake During First Year of Mechanical Circulatory Support in End-Stage Heart Failure Patients - Follow Up on PRO-VAD Study. J Heart Lung Transplant 2023. [DOI: 10.1016/j.healun.2023.02.780] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023] Open
|
9
|
ONSET OF ACTION OF AZELASTINE HCL NASAL SPRAY 0.15% EVALUATED IN AN ENVIRONMENTAL EXPOSURE CHAMBER. Ann Allergy Asthma Immunol 2022. [DOI: 10.1016/j.anai.2022.08.704] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
10
|
CNAViz: An interactive webtool for user-guided segmentation of tumor DNA sequencing data. PLoS Comput Biol 2022; 18:e1010614. [PMID: 36228003 PMCID: PMC9595559 DOI: 10.1371/journal.pcbi.1010614] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2022] [Revised: 10/25/2022] [Accepted: 09/29/2022] [Indexed: 11/05/2022] Open
Abstract
Copy-number aberrations (CNAs) are genetic alterations that amplify or delete the number of copies of large genomic segments. Although they are ubiquitous in cancer and, thus, a critical area of current cancer research, CNA identification from DNA sequencing data is challenging because it requires partitioning of the genome into complex segments with the same copy-number states that may not be contiguous. Existing segmentation algorithms address these challenges either by leveraging the local information among neighboring genomic regions, or by globally grouping genomic regions that are affected by similar CNAs across the entire genome. However, both approaches have limitations: overclustering in the case of local segmentation, or the omission of clusters corresponding to focal CNAs in the case of global segmentation. Importantly, inaccurate segmentation will lead to inaccurate identification of CNAs. For this reason, most pan-cancer research studies rely on manual procedures of quality control and anomaly correction. To improve copy-number segmentation, we introduce CNAViz, a web-based tool that enables the user to simultaneously perform local and global segmentation, thus overcoming the limitations of each approach. Using simulated data, we demonstrate that by several metrics, CNAViz allows the user to obtain more accurate segmentation relative to existing local and global segmentation methods. Moreover, we analyze six bulk DNA sequencing samples from three breast cancer patients. By validating with parallel single-cell DNA sequencing data from the same samples, we show that by using CNAViz, our user was able to obtain more accurate segmentation and improved accuracy in downstream copy-number calling. Copy-number aberrations (CNAs) are large genetic alterations that are pervasive in cancer and, therefore, have been the focus of several cancer research studies. Copy-number segmentation is a key step in the process of CNA identification, which consist in partitioning the genome into genomic segments with the same copy-number state. However, segmentation is challenging and the limitations of current segmentation algorithms lead to inaccuracies in the characterization of CNAs. In this paper, we introduce CNAViz, an interactive web-based tool that enables the user to edit segmentation solutions and overcome current limitations. We demonstrate the ability of a user to use CNAViz to improve segmentation solutions on both simulated and real data, analyzing six published bulk DNA sequencing samples from three breast cancer patients. Finally, we demonstrate that these improvements in segmentation solutions improve accuracy in downstream copy-number calling, enabling more accurate analyses of intra-tumor heterogeneity.
Collapse
|
11
|
WashU Epigenome Browser update 2022. Nucleic Acids Res 2022; 50:W774-W781. [PMID: 35412637 PMCID: PMC9252771 DOI: 10.1093/nar/gkac238] [Citation(s) in RCA: 38] [Impact Index Per Article: 19.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2022] [Revised: 03/08/2022] [Accepted: 03/28/2022] [Indexed: 12/22/2022] Open
Abstract
WashU Epigenome Browser (https://epigenomegateway.wustl.edu/browser/) is a web-based genomic data exploration tool that provides visualization, integration, and analysis of epigenomic datasets. The newly renovated user interface and functions have enabled researchers to engage with the browser and genomic data more efficiently and effectively since 2018. Here, we introduce a new integrated panel design in the browser that allows users to interact with 1D (genomic features), 2D (such as Hi-C), 3D (genome structure), and 4D (time series) data in a single web page. The browser can display three-dimensional chromatin structures with the 3D viewer module. The 4D tracks, called ‘Dynamic’ tracks, animatedly display time-series data, allowing for a more striking visual impact to identify the gene or genomic region candidates as a function of time. Genomic data, such as annotation features, numerical values, and chromatin interaction data can all be viewed in the dynamic track mode. Imaging data from microscopy experiments can also be displayed in the browser. In addition to software development, we continue to service and expand the data hubs we host for large consortia including 4DN, Roadmap Epigenomics, TaRGET and ENCODE, among others. Our growing user/developer community developed additional track types as plugins, such as qBed and dynseq tracks, which extend the utility of the browser. The browser serves as a foundation for additional genomics platforms including the WashU Virus Genome Browser (for COVID-19 research) and the Comparative Genome Browser. The WashU Epigenome Browser can also be accessed freely through Amazon Web Services at https://epigenomegateway.org/.
Collapse
|
12
|
Cell-Free DNA to Distinguish High Risk Donor Specific Antibodies in Heart Transplantation. J Heart Lung Transplant 2022. [DOI: 10.1016/j.healun.2022.01.1209] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
13
|
Right Ventricle Pressure-Volume Analysis During LVAD Explant Evaluation. J Heart Lung Transplant 2022. [DOI: 10.1016/j.healun.2022.01.1724] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
14
|
Circulating microRNA Biomarkers in Cellular and Antibody-Mediated Heart Transplant Rejection. J Heart Lung Transplant 2022. [DOI: 10.1016/j.healun.2022.01.216] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
15
|
Unsupervised Machine Learning to Identify and Target Myofilament Mechanisms of Clinical RV Dysfunction in HFrEF. J Heart Lung Transplant 2022. [DOI: 10.1016/j.healun.2022.01.356] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
16
|
The qBED track: a novel genome browser visualization for point processes. Bioinformatics 2021; 37:1168-1170. [PMID: 32941613 DOI: 10.1093/bioinformatics/btaa771] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2020] [Revised: 08/10/2020] [Accepted: 09/15/2020] [Indexed: 01/25/2023] Open
Abstract
SUMMARY Transposon calling cards is a genomic assay for identifying transcription factor binding sites in both bulk and single cell experiments. Here, we describe the qBED format, an open, text-based standard for encoding and analyzing calling card data. In parallel, we introduce the qBED track on the WashU Epigenome Browser, a novel visualization that enables researchers to inspect calling card data in their genomic context. Finally, through examples, we demonstrate that qBED files can be used to visualize non-calling card datasets, such as Combined Annotation-Dependent Depletion scores and GWAS/eQTL hits, and thus may have broad utility to the genomics community. AVAILABILITY AND IMPLEMENTATION The qBED track is available on the WashU Epigenome Browser (http://epigenomegateway.wustl.edu/browser), beginning with version 46. Source code for the WashU Epigenome Browser with qBED support is available on GitHub (http://github.com/arnavm/eg-react and http://github.com/lidaof/eg-react). A complete definition of the qBED format is available as part of the WashU Epigenome Browser documentation (https://eg.readthedocs.io/en/latest/tracks.html#qbed-track). We have also released a tutorial on how to upload qBED data to the browser (http://dx.doi.org/10.17504/protocols.io.bca8ishw).
Collapse
|
17
|
Natriuretic Peptide Levels and Clinical Outcomes among Patients Hospitalized with COVID-19 Infection. J Heart Lung Transplant 2021. [PMCID: PMC7979424 DOI: 10.1016/j.healun.2021.01.606] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
Purpose There is increasing evidence of adverse cardiovascular morbidity associated with SARS-CoV-2 (COVID-19). Pro-B-type natriuretic peptide (proBNP) is a biomarker of myocardial stress associated with outcomes in various respiratory and cardiac diseases. We hypothesized that proBNP level would be associated with mortality and clinical outcomes in hospitalized COVID-19 patients. Methods We performed a retrospective analysis of hospitalized COVID-19 patients (n=1232) using adjusted logistic and linear regression to assess the association of admission proBNP (analyzed by both categorical cutoff >125 pg/mL and continuous log transformed proBNP) with clinical outcomes. Covariates included age, sex, race, body mass index (BMI), hypertension, coronary artery disease (CAD), diabetes, smoking history, and chronic kidney disease stage (Model 1), with Troponin I added in Model 2. We performed survival analysis by a multivariate Cox proportional hazard model, incorporating log transformed proBNP. We additionally treated BMI, a strong potential confounder of both proBNP levels and COVID-19 outcomes, as an ordinal variable ordered across tertiles. Results Patients were mean age 62.9±17.6, 53.8% male, and 35.9% Black. Preadmission comorbidities were hypertension (57.1%), diabetes (31.6%), CAD (9.0%) and heart failure (HF, 10.6%). In Model 1 and 2, higher proBNP level was significantly associated with death, new HF, length of stay, ICU duration and need for ventilation among hospitalized COVID-19 patients. This significance persisted after ordinal compression of BMI across tertiles. The adjusted hazard ratio of death for log[proBNP] was 1.56 (95% CI: 1.23-1.97; P<0.0001). Conclusion Using a relatively large and racially diverse hospitalized COVID-19 patient cohort, we find that proBNP is associated with adverse clinical outcomes, including mortality and new HF in COVID-19. Further prospective investigation is warranted on the utility of proBNP for clinical prognostication in COVID-19.
Collapse
|
18
|
Impact of Pre-Transplant ECMO Duration on Heart Transplant Survival. J Heart Lung Transplant 2021. [DOI: 10.1016/j.healun.2021.01.1946] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
19
|
Myocarditis as a Manifestation of a T Cell Lymphoproliferative Disorder in a Patient Undergoing Left Ventricular Assistance Device Implantation. J Heart Lung Transplant 2021. [DOI: 10.1016/j.healun.2021.01.2102] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
20
|
Cardiac Allograft Injury in Patients of African Ancestry: Trends of Donor-Derived Cell-Free DNA Based on Genetic Ancestry. J Heart Lung Transplant 2021. [DOI: 10.1016/j.healun.2021.01.725] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
21
|
WashU Epigenome Browser update 2019. Nucleic Acids Res 2020; 47:W158-W165. [PMID: 31165883 PMCID: PMC6602459 DOI: 10.1093/nar/gkz348] [Citation(s) in RCA: 166] [Impact Index Per Article: 41.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2019] [Revised: 04/23/2019] [Accepted: 05/31/2019] [Indexed: 12/20/2022] Open
Abstract
The WashU Epigenome Browser (https://epigenomegateway.wustl.edu/) provides visualization, integration and analysis tools for epigenomic datasets. Since 2010, it has provided the scientific community with data from large consortia including the Roadmap Epigenomics and the ENCODE projects. Recently, we refactored the codebase, redesigned the user interface, and developed various novel features. New features include: (i) visualization using virtual reality (VR), which has implications in biology education and the study of 3D chromatin structure; (ii) expanded public data hubs, including data from the 4DN, ENCODE, Roadmap Epigenomics, TaRGET, IHEC and TCGA consortia; (iii) a more responsive user interface; (iv) a history of interactions, which enables undo and redo; (v) a feature we call Live Browsing, which allows multiple users to collaborate remotely on the same session; (vi) the ability to visualize local tracks and data hubs. Amazon Web Services also hosts the redesign at https://epigenomegateway.org/.
Collapse
|
22
|
Early Donor-Derived Cell-Free DNA Predicts Peak Allograft Function in Heart Transplant. J Heart Lung Transplant 2020. [DOI: 10.1016/j.healun.2020.01.1261] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
23
|
Management of Heart Failure in Left Ventricular Assist Device (LVAD) Patients Utilizing an Outpatient Diuresis Clinic. J Heart Lung Transplant 2020. [DOI: 10.1016/j.healun.2020.01.400] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
24
|
De Novo Malignancy after Heart Transplantation. J Heart Lung Transplant 2020. [DOI: 10.1016/j.healun.2020.01.1020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
25
|
Increased Cell Free DNA Levels in African American Patients Early after Heart Transplantation. J Heart Lung Transplant 2020. [DOI: 10.1016/j.healun.2020.01.922] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
26
|
Association between Pretransplant Antibody against Angiotensin II Type 1 Receptor and Posttransplant Allograft Injury. J Heart Lung Transplant 2020. [DOI: 10.1016/j.healun.2020.01.1175] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
27
|
Less Invasive Surgical Implant Strategy is Associated with Significant Reduction in INTERMACS Defined Right Heart Failure Following LVAD Implantation. J Heart Lung Transplant 2020. [DOI: 10.1016/j.healun.2020.01.1005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
28
|
Right Atrial Pacing to Improve Acute Hemodynamics in Pulmonary Arterial Hypertension. J Heart Lung Transplant 2020. [DOI: 10.1016/j.healun.2020.01.1146] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
29
|
Kussmaul's Sign Correlates with Pulmonary Vascular Pathology and Reduced Exercise Right Ventricular Output Reserve. J Heart Lung Transplant 2020. [DOI: 10.1016/j.healun.2020.01.733] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
30
|
Comparable efficacy and safety of brodalumab in obese and nonobese patients with psoriasis: analysis of two randomized controlled trials. Br J Dermatol 2019; 182:880-888. [DOI: 10.1111/bjd.18327] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/02/2019] [Indexed: 12/21/2022]
|
31
|
Use of dupilumab in patients who are HIV‐positive: report of four cases. Br J Dermatol 2019; 181:1311-1312. [DOI: 10.1111/bjd.18222] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
|
32
|
P1021Comparative efficacy of microfidelity technology vs standard ablation for atrioventricular nodal ablation. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz747.0612] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Microfidelity Cateter Technology has proven efficacy in ablating atrial arrhythmias in multiple pilot studies. Closely spaced radial microelectrodes render a focused near-field electrogram. Case series suggest that this catheter design facilitates accurate ablations with fewer radiofrequency (RF) lesions. Atrioventricular junction (AVJ) ablation is regarded as a straightforward procedure, but case records show wide variance in procedure times and number of RF lesions required.
Methods
Twenty-four patients scheduled for AVJ ablation were randomized to treatment with either the Microfidelity technology or standard 8mm/8 French ablation catheter. Both groups located the AVJ by fluoroscopic landmarks and His electrograms, and the MiFi group used electroanatomical mapping to create the location of his electrograms. The primary endpoints were development of Junctional Rhythm (JR) or Complete Heart Block (CHB), and time from first RF lesion until rhythm change. Secondary endpoints included number of RF applications.
Results
Patients were randomized one-to-one to the MiFi arm or standard ablation arm. JR or CHB was achieved in all patients. Time from first RF lesion until JR/CHB was: (Median/IQR) 325 sec/250–1270 sec. vs 287 sec/101–406 sec. Number of RF applications was 5/3–15 applications vs 4.5/1–5 applications. Total procedure time in the lab was 134 min/73.5–172.5 min vs 58 min/52–146 min.
Microfidelity Technology vs Standard
Conclusion
Analysis suggests that the MiFi catheter is efficacious in ablating the AVJ, but requires greater RF duration and number of lesions, with wider case-by-case variability to achieve JR or CHB. Microfidelity technology and electroanatomical mapping did not result in faster time to completion than using fluoroscopic landmarks and His electrograms alone. Preoperative choice of sheath for catheter stability and contact may also play a role in a more efficient timely successful ablation of the AV node.
Acknowledgement/Funding
Boston Scientific
Collapse
|
33
|
P1675Evolution of lactate dehydrogenase levels in patients with HeartMate II, HeartWare and HeartMate 3 left ventricular assist devices during first-year follow-up. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz748.0431] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Lactate dehydrogenase (LDH) is considered as a biomarker of thrombotic events in patients receiving a left ventricular assist device (LVAD).
Purpose
This study aimed to investigate the evolution of LDH levels over time between patients supported with a HeartMate II (HMII), HeartMate 3 (HM3) or HeartWare (HVAD) LVAD during their first-year post implantation.
Methods
We analyzed in this multi-center retrospective study, all patients with HMII, HM3 and HVAD LVAD implanted between December 2006 and April 2017. Patients were classified into three groups based on their device type. Loess splines over time were used to depict the repeated measurements of LDH.
Results
In total, 134 patients received an LVAD (77% male, mean age 55 [46–61]), of whom 64 (48%) were HMII, 22 (16%) HM3 and 48 (36%) were HVAD. Loess splines over time indicate that there could be a considerable difference between evolution of LDH (Figure). During the first-year follow-up, 3 (5%) patients had a confirmed and 10 (16%) patients had a suspected pump thrombosis in the HMII group. For the HVAD, there were 6 (13%) patients with confirmed thrombosis and 1 (2%) case of suspected thrombosis, whereas none of the patients in the HM3 group experienced a suspected or confirmed pump thrombosis (p=0.01). The 1-year overall survival rate for HM II, HM3 and HVAD was 84%, 86% and 72% respectively (p=0.311). The overall stroke-free rate at one year was: 89%, 77% and 91% for HMII, HVAD and HM3 respectively (p=0.15).
Means of observed LDH values over time
Conclusion
During the first-year post LVAD implantation, there appear to be different evolutions of LDH levels over time in HMII device patients compared to HVAD or HM3 device patients. Given differences in baseline hemolysis levels between devices, currently used LDH thresholds for detection of impending pump thrombosis may be less sensitive and thus thresholds may be device specific.
Collapse
|
34
|
Impact of Left Ventricular Assist Device Placement on Chronic Kidney Diseases: A Multicenter Longitudinal Study. J Heart Lung Transplant 2019. [DOI: 10.1016/j.healun.2019.01.573] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
35
|
Clinical Surrogates of Right Ventricular-Pulmonary Arterial Uncoupling. J Heart Lung Transplant 2019. [DOI: 10.1016/j.healun.2019.01.222] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
36
|
Circulating, Cell-Free, MicroRNA Sequencing to Diagnose Cardiac Allograft Rejection and Distinguish Rejection Subtype. J Heart Lung Transplant 2019. [DOI: 10.1016/j.healun.2019.01.115] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
37
|
Brodalumab in patients who had inadequate response to ustekinumab. Br J Dermatol 2019. [DOI: 10.1111/bjd.17471] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
38
|
Brodalumab 用于对乌司奴单抗应答不足的患者. Br J Dermatol 2019. [DOI: 10.1111/bjd.17484] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
39
|
Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: subgroup analysis of two randomized phase III trials. Br J Dermatol 2018; 180:306-314. [PMID: 30328108 DOI: 10.1111/bjd.17318] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/06/2018] [Indexed: 01/23/2023]
Abstract
BACKGROUND Brodalumab, a fully human anti-interleukin-17 receptor A monoclonal antibody, has demonstrated superior efficacy and safety over ustekinumab as induction therapy for moderate-to-severe psoriasis. OBJECTIVES To evaluate the efficacy and safety of brodalumab through week 52 in patients who had inadequate responses to ustekinumab. METHODS A subgroup analysis of the phase III AMAGINE-2/-3 double-blind randomized controlled trials was performed. Participants were aged 18-75 years and had a Psoriasis Area and Severity Index (PASI) ≥ 12, static Physician's Global Assessment score ≥ 3 and involvement of ≥ 10% body surface area. The studies were registered at ClinicalTrials.gov: AMAGINE-2, NCT01708603; AMAGINE-3, NCT01708629. RESULTS At baseline, patients with or without prior biologic experience who had an adequate response at week 16 on ustekinumab or brodalumab had lower rates of involved body surface area, PASI, prior biologic use, psoriatic arthritis and body mass index than patients who experienced inadequate response at or after week 16. Among patients who experienced inadequate response to ustekinumab, those rescued with brodalumab had PASI ≥ 75%, ≥ 90% and 100% improvement response rates of 72·6%, 58·1% and 36·3%, respectively, at week 52 compared with 61·7%, 25·5% and 5·4%, respectively, in patients who continued ustekinumab. Exposure-adjusted rates of treatment-emergent adverse events were similar among patients rescued with brodalumab (377·3 adverse events per 100 patient-years) and those who remained on ustekinumab (389·9 adverse events per 100 patient-years). CONCLUSIONS Among patients who experienced inadequate responses to ustekinumab, rescue with brodalumab improved skin clearance outcomes compared with continuing ustekinumab.
Collapse
|
40
|
Validation of simultaneous preimplantation genetic testing (PGT) for aneuploidy, monogenic, and polygenic disorders. Fertil Steril 2018. [DOI: 10.1016/j.fertnstert.2018.07.313] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
41
|
5992Improved haemocompatibility in the heartmate 3 left ventricular assist device assessed through lactate dehydrogenase levels over time. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy566.5992] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
42
|
P5120Pre-operative liver dysfunction is associated with higher mortality rates at 1-year after left ventricular assist device implantation. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy566.p5120] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
43
|
Validation of Donor-derived Cell-free DNA to Detect Heart-transplant Rejection. J Heart Lung Transplant 2018. [DOI: 10.1016/j.healun.2018.01.178] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
44
|
Improvement in itch and other psoriasis symptoms with brodalumab in phase 3 randomized controlled trials. J Eur Acad Dermatol Venereol 2018; 32:1305-1313. [PMID: 29512200 DOI: 10.1111/jdv.14913] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2017] [Accepted: 01/22/2018] [Indexed: 02/06/2023]
Abstract
BACKGROUND Patients with psoriasis have lesional symptoms, including itch, which can reduce quality of life. The efficacy and safety of brodalumab, an interleukin-17 receptor A antagonist, in treating moderate-to-severe psoriasis have been reported in three randomized, controlled, phase 3 trials (AMAGINE-1/-2/-3). OBJECTIVE The effect of brodalumab on lesional symptoms was assessed using the psoriasis symptom inventory (PSI), a validated patient-reported instrument. METHODS Patients were randomized to receive brodalumab (140 or 210 mg every 2 weeks [Q2W]), placebo (AMAGINE-1/-2/-3), or ustekinumab (AMAGINE-2/-3) during a 12-week induction phase, followed by a maintenance phase through week 52. Patients electronically rated the severity of PSI items (itch, burning, stinging, pain, redness, scaling, cracking and flaking) during the previous 24 h on a scale of 0 (not at all severe) to 4 (very severe). At each visit, the PSI total score responder status was assessed, with responders defined as having an average weekly total inventory score ≤8 with no item score >1 at week 12. RESULTS Across AMAGINE-1/-2/-3, brodalumab was associated with improvements in PSI total scores and itch scores vs. placebo from week 2 through week 12 (P < 0.001 in both domains). In AMAGINE-2/-3, brodalumab 210 mg Q2W demonstrated faster onset of PSI total score and itch responses (week 2, 22.1% and 36.4%, respectively) vs. ustekinumab (week 2, 6.9% and 17.1%, respectively) and was associated with improved itch responses vs. ustekinumab after 52 weeks of constant treatment. CONCLUSION Brodalumab demonstrated rapid, robust improvements in symptoms assessed by the PSI, including itch, vs. placebo and ustekinumab.
Collapse
|
45
|
ACTIVE AGING AND INTERNET USE: DOES INEQUALITY EXIST ACROSS AREAS AND OLDER ADULTS? Innov Aging 2017. [DOI: 10.1093/geroni/igx004.4320] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
46
|
SELF-RATED HEALTH AND THE COMBINATIONS OF SELF-CARE DISABILITIES AMONG DISABLED ELDERS IN TAIWAN. Innov Aging 2017. [DOI: 10.1093/geroni/igx004.1919] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
47
|
MRI-guided radiotherapy for head and neck cancer: initial clinical experience. Clin Transl Oncol 2017; 20:160-168. [DOI: 10.1007/s12094-017-1704-4] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2017] [Accepted: 06/05/2017] [Indexed: 01/16/2023]
|
48
|
Human Right Ventricular Myofilaments Exhibit Directionally Opposite Changes in Maximal Force and Calcium Sensitivity in Systemic Sclerosis-Associated versus Idiopathic Pulmonary Arterial Hypertension. J Heart Lung Transplant 2017. [DOI: 10.1016/j.healun.2017.01.184] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
49
|
Abstract
Previous studies have reported that blue light (400–500 nm) inhibits cell mitochondrial activity. We investigated the hypothesis that cells with high energy consumption are most susceptible to blue-light-induced mitochondrial inhibition. We estimated cell energy consumption by population doubling time, and cell survival and growth by succinate dehydrogenase (SDH) activity. Six cell types were exposed to 5 or 60 J/cm2 of blue light from quartz-tungsten-halogen (QTH), plasma-arc (PAC), or argon laser sources in monolayer culture. Post-light SDH activity correlated positively with population doubling time (R2 = 0.91 for PAC, 0.76 for QTH, 0.68 for laser); SDH activity increased for cell types with the longest doubling times and was suppressed for cell types with shorter doubling times. Thus, light-induced exposure differentially affects SDH activity, cell survival, and growth, depending on cell energy consumption. Blue light may be useful as a therapeutic modulator of cell growth and survival.
Collapse
|
50
|
SU-F-J-169: A Feasibility Study of Using MRI Alone in Abdominal Radiotherapy. Med Phys 2016. [DOI: 10.1118/1.4956077] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|